Guardant Health (STU:5GH) Dividends per Share : €0.00 (TTM As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Guardant Health Dividends per Share?

Guardant Health's dividends per share for the three months ended in Sep. 2024 was €0.00. Its dividends per share for the trailing twelve months (TTM) ended in Sep. 2024 was €0.00. Its Dividend Payout Ratio for the three months ended in Sep. 2024 was 0.00. As of today, Guardant Health's Dividend Yield % is 0.00%.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

For more information regarding to dividend, please check our Dividend Page.

* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.

Guardant Health Dividends per Share Historical Data

The historical data trend for Guardant Health's Dividends per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Guardant Health Dividends per Share Chart

Guardant Health Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dividends per Share

Get a 7-Day Free Trial

Guardant Health Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Dividends per Share	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Guardant Health's Dividends per Share

For the Diagnostics & Research subindustry, Guardant Health's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Guardant Health's Dividend Yield % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Guardant Health's Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Guardant Health's Dividend Yield % falls into.

Guardant Health Dividends per Share Calculation

Dividends paid to per common share.

Guardant Health (STU:5GH) Dividends per Share Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

Guardant Health's Dividend Payout Ratio for the quarter that ended in Sep. 2024 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Sep. 2024 )	/	EPS without NRI (Q: Sep. 2024 )
	=	0	/	-0.793
	=	N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

Guardant Health Dividends per Share Related Terms

Thank you for viewing the detailed overview of Guardant Health's Dividends per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Guardant Health Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Guardant Health Inc (STU:5GH) » Definitions » Dividends per Share

Comparable Companies

Traded in Other Exchanges

GH:USA GH:Mexico 5GH:Germany

Address

3100 Hanover Street, Palo Alto, CA, USA, 94304

Website

https://www.guardanthealth.com

Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.

Guardant Health Headlines

No Headlines